NeuroThera Labs Inc.
Neurothera Labs Inc. operates a clinical-stage pharmaceutical company. The company engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. Neurothera Labs Inc. was formerly known as Miza III Ventu… Read more
NeuroThera Labs Inc. (NTLX) - Net Assets
Latest net assets as of April 2025: CA$909.01K CAD
Based on the latest financial reports, NeuroThera Labs Inc. (NTLX) has net assets worth CA$909.01K CAD as of April 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.07 Million) and total liabilities (CA$165.45K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$909.01K |
| % of Total Assets | 84.6% |
| Annual Growth Rate | -11.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 7.09 |
NeuroThera Labs Inc. - Net Assets Trend (2022–2025)
This chart illustrates how NeuroThera Labs Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NeuroThera Labs Inc. (2022–2025)
The table below shows the annual net assets of NeuroThera Labs Inc. from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | CA$924.63K | -21.65% |
| 2024-01-31 | CA$1.18 Million | -7.43% |
| 2023-01-31 | CA$1.27 Million | -5.90% |
| 2022-01-31 | CA$1.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeuroThera Labs Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44003900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$1.52 Million | 164.66% |
| Total Equity | CA$924.63K | 100.00% |
NeuroThera Labs Inc. Competitors by Market Cap
The table below lists competitors of NeuroThera Labs Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENERGY METALS
MU:E9M
|
$1.04K |
|
European Energy Metals Corp.
OTCQB:EUEMF
|
$1.04K |
|
ECR Minerals plc
LSE:ECR
|
$1.04K |
|
MOONLIGHT FPO [ML8]
AU:ML8
|
$1.04K |
|
Eagle Royalties Ltd.
OTCGREY:ERYTF
|
$1.03K |
|
Velocity Composites plc
LSE:VEL
|
$1.03K |
|
Arab Moltaka Investments Co
EGX:AGIG
|
$1.03K |
|
Sunshine Holdings PLC
CM:SUNN0000
|
$1.03K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeuroThera Labs Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,180,088 to 924,629, a change of -255,459 (-21.6%).
- Net loss of 255,459 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-255.46K | -27.63% |
| Total Change | CA$- | -21.65% |
Book Value vs Market Value Analysis
This analysis compares NeuroThera Labs Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.06x to 3.03x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-01-31 | CA$0.08 | CA$0.16 | x |
| 2023-01-31 | CA$0.07 | CA$0.16 | x |
| 2024-01-31 | CA$0.07 | CA$0.16 | x |
| 2025-01-31 | CA$0.05 | CA$0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeuroThera Labs Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.17x
- Recent ROE (-27.63%) is below the historical average (-13.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -11.28% | 0.00% | 0.00x | 1.01x | CA$-288.26K |
| 2023 | -6.26% | 0.00% | 0.00x | 1.01x | CA$-207.34K |
| 2024 | -8.87% | 0.00% | 0.00x | 1.04x | CA$-222.72K |
| 2025 | -27.63% | 0.00% | 0.00x | 1.17x | CA$-347.92K |
Industry Comparison
This section compares NeuroThera Labs Inc.'s net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $320,719
- Average return on equity (ROE) among peers: -15.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeuroThera Labs Inc. (NTLX) | CA$909.01K | -11.28% | 0.18x | $1.04K |
| First Tidal Acquisition Corp. (AAA-P) | $271.64K | -12.76% | 0.07x | $106.95K |
| AAJ Capital 3 Corp. (AAAJ-P) | $176.31K | -28.45% | 0.14x | $50.13K |
| AD4 Capital Corp. (ADJ-P) | $498.36K | 0.00% | 0.06x | $10.44K |
| AF2 Capital Corp (AF-P) | $125.52K | -22.68% | 0.19x | $45.26K |
| AIM5 Ventures Inc (AIME-P) | $236.65K | -15.61% | 0.12x | $151.51K |
| Apolo IV Acquisition Corp (AIV-P) | $1.13 Million | -19.92% | 0.03x | $33.42K |
| A-Labs Capital II Corp (ALAB-P) | $166.02K | -34.30% | 0.10x | $38.61K |
| Albatros Acquisition Corporation Inc. (ALBT-P) | $155.00K | 0.00% | 0.13x | $13.43K |
| Altina Capital Corp (ALTN-P) | $-3.34K | 0.00% | 0.00x | $65.59K |
| AMG Acquisition Corp (AMG-P) | $454.39K | -24.61% | 0.02x | $54.31K |